ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "dermatomyositis"

  • Abstract Number: 2670 • ACR Convergence 2025

    Real-World Experience of Anifrolumab in 24 Patients with Refractory Dermatomyositis: A Multicenter Retrospective Study.

    Miriam Retuerto Guerrero1, Clara Moriano2, Ana Pareja-Martínez3, Natalia Molina-Esteban4, Jose Puig-Buendia5, Concepción Postigo-Llorente5, Ana Lopez-Ceron Cofiño6, Julia Martínez Barrio7, Paola Vidal-Montal8, Elena Sendagorta Cudos9, GUILLERMO GONZALEZ ARRIBAS10, Jaime Calvo11, Juan Ramon De Dios12, Juan María Blanco-Madrigal13, Paloma Vela Casasempere14, Javier Bachiller15, Concepción Fito-Manteca16, Carmen Ordas calvo17, Luisa Martos Cabrera18, Alejandro Sanchez Herrero19, Luis Ortega-Valin20 and Elvira Diez Alvarez21, 1Complejo Asistencial Universitario de León, Leon, Castilla y Leon, Spain, 2Hospital León, LEON, Castilla y Leon, Spain, 3Rheumatology. Hospital Universitario Infanta Leonor, Madrid, Madrid, Spain, 4Rheumatology. Hospital Universitario 12 de octubre, Madrid, Madrid, Spain, 5Dermatology. Hospital universitario 12 de octubre, Madrid, Madrid, Spain, 6Rheumatology. Complejo Asistencial Universitario de Soria, Soria, Castilla y Leon, Spain, 7Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, 8Rheumatology. Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain, 9Dermatology. Hospital universitario La Paz, Madrid, Madrid, Spain, 10Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, 11Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, 12Department of Rheumatology. Hospital Universitario Araba. Instituto de Investigación Sanitaria BIORABA., Vitoria, Pais Vasco, Spain, 13Rheumatology. Hospital Universitario Araba., Vitoria, Pais Vasco, Spain, 14Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, 15Hospital Ramon y Cajal, Madrid, Madrid, Spain, 16Rheumatology. Hospital Universitario de Navarra., Pamplona, Navarra, Spain, 17Rheumatology. Hospital Universitario de Cabueñes., Gijon, Asturias, Spain, 18Dermatology. Hospital Universitario de La Princesa, Madrid, Madrid, Spain, 19Dermatology. Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain, 20Pharmacy. Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain, 21Rheumatology. Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain

    Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease marked by muscle weakness and characteristic cutaneous manifestations. Dysregulation of the Type I interferon (IFN-I) pathway plays…
  • Abstract Number: 2055 • ACR Convergence 2025

    Construct Validity of Total Improvement Score (TIS) as an Endpoint for Clinically Meaningful Improvement in Multiple Patient-Centered Outcome Measures in Dermatomyositis

    Anjana Chandrasekhara Pillai1, Shiri Keret2, Siamak Moghadam-Kia3, Chester V. Oddis4 and Rohit Aggarwal5, 1PPCP, Pittsburgh, PA, 2Bnai Zion Medical Center, Atlit, Israel, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4University of Pittsburgh, Pittsburgh, PA, 5University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA

    Background/Purpose: Total Improvement Score (TIS), as defined by the ACR/EULAR myositis response criteria, is increasingly employed as a primary endpoint in clinical trials for dermatomyositis…
  • Abstract Number: 1208 • ACR Convergence 2025

    Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression

    Jia Shi1, Yang Wu2, Aviya Levy3, Ting Wang4, Abhinav Janappareddi5, Payton Hermanson1, Jorge A. Gonzalez-Chapa5, Qian Wang6, Susan Shenoi7 and Christian Lood5, 1University of Washington, Seattle, WA, 21. Chinese Academy of Medical Sciences & Peking Union Medical College; 2. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China; 3. University of Washington, Division of Rheumatology, Seattle, WA, USA, Beijing, China (People's Republic), 3Rady Children's Hospital, San Diego, CA, 4Division of Rheumatology, Seattle Children's Hospital and Research Center, Seattle, 5University of Washington, Division of Rheumatology, Seattle, 6Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), 7Seattle Children's Hospital and Research Center, Mercer Island, WA

    Background/Purpose: Juvenile dermatomyositis (JDM) is an inflammatory vasculopathy characterized by muscle weakness and systemic inflammation. This study aimed to investigate the clinical utility of neutrophil…
  • Abstract Number: 0290 • ACR Convergence 2025

    Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey

    Ezgi Sahin1, Omer Uludag2, yasemin yalcinkaya3, Bahar Artim Esen4, Ahmet Gul3 and Murat Inanc3, 1Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, 2Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 3Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, 4Istanbul University, Istanbul, Istanbul, Turkey

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases characterized by muscle weakness, often involving other organs such as the skin, lungs, and heart. Defined…
  • Abstract Number: 2669 • ACR Convergence 2025

    RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies

    Erin Wilfong1, Tahseen Mozaffar2, Elie Naddaf3, Nizar Chahin4, Huifang Lu5, Iazsmin Bauer Ventura6, Courtney Little7, Carl diCasoli7, Claire Miller8, Jenell Volkov7, Daniel Nunez7, Thomas Furmanak7, Jason Stadanlick7, Larissa Ishikawa7, Zachary Vorndran7, Alexandra Ellis7, Jazmean Williams7, Steve Flanagan7, Quynh Lam8, Fatemeh Hadi-Nezhad8, Raj Tummala8, Samik Basu7 and David Chang9, 1Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, 2University of California, irvine, Orange, CA, 3Mayo Clinic, Rochester, MN, 4Oregon Health & Science University, Portland, 5UT MD Anderson Cancer Center, Houston, TX, 6University of Chicago, Chicago, IL, 7Cabaletta Bio, Philadelphia, PA, 8Cabaletta Bio, Philadelphia, 9Cabaletta Bio, Bryn Mawr, PA

    Background/Purpose: The goals of treatment for idiopathic inflammatory myopathy (IIM) are to eliminate or reduce inflammation, restore muscle performance, reduce morbidity, and improve a patient’s…
  • Abstract Number: 2053 • ACR Convergence 2025

    A Prospective Study Unveils Damage Accrual and Myositis Specific Antibodies as Key Risk Factors for Mortality in Myositis

    Agustin Hernández-López1, Nancy R Mejía Domínguez2, Yatzil Reyna Juárez3, María José Ostos Prado4, Beatriz Alcalá Carmona5, Jennifer Tiaré Balderas Miranda6, Carlos A. Núñez-Álvarez5, Marta E. Baños-Laredo7, Diana Gómez-Martín8 and Jiram Torres-Ruiz9, 1Instituo Nacional de Ciencias Médicas y Nutricion Salvador Zubirán, Morelia, Michoacan de Ocampo, Mexico, 2Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 3Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, 4Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, 5INCMNSZ, Cdmx, Distrito Federal, Mexico, 6Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, 7INCMNSZ, Cdmx, Mexico, 8INCMNSZ, Mexico city, Federal District, Mexico, 9INCMNSZ, Ciudad de México, Mexico

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by muscular inflammation that can affect any organ or system. Reported mortality rates…
  • Abstract Number: 1207 • ACR Convergence 2025

    Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis

    Jesus Valencia1, Will Kelly1, Sean Tackett2, Amanda Finney1, Jemima Albayda1, Julie Paik3, Lisa Christopher-Stine1 and Chris Mecoli4, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University, Baltimore, 3Johns Hopkins Rheumatology, Baltimore, MD, 4Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by cutaneous manifestations and proximal muscle inflammation.1,2 Notably, the clinical course of muscular and cutaneous disease…
  • Abstract Number: 0287 • ACR Convergence 2025

    Comprehensive Profiling of Neutrophil Subsets Reveals Functional Signatures Linked to Vasculopathic Features in Patients with Inflammatory Myopathies

    Daniel Alberto Carrillo-Vázquez1, Beatriz Alcalá-Carmona1, Jennifer Tiaré Balderas Miranda2, Yatzil Reyna Juárez3, María José Ostos Prado1, Samuel Govea-Peláez1, Nancy R Mejía Domínguez4, Guillermo Juárez Vega4, Karina Santana-De Anda1, Jiram Torres-Ruiz5 and Diana Gómez-Martín6, 1Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, 2Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, 3Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, 4Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 5INCMNSZ, Ciudad de México, Mexico, 6INCMNSZ, Mexico city, Federal District, Mexico

    Background/Purpose: Vasculopathic manifestations of idiopathic inflammatory myopathies (IIM) such as interstitial lung disease (ILD), calcinosis, skin ulcers, mechanic’s hands, are characterized by immune-mediated vascular damage.…
  • Abstract Number: 2668 • ACR Convergence 2025

    CD14⁺ Myeloid Cells Mediate UVB Photosensitivity in Autoimmune Skin Disease via a Spatially Resolved Inflammatory Circuit

    Nazgol Haddadi1, Khashayar Afshari1, Yuqing Wang1, Carolina S. Lopes1, Chee-Huat L. Eng2, Nuria Martinez-Gutierrez1, Leah Whiteman1, Kevin Wei3, Kirsten Frieda2, Stefania Gallucci1, Misha Rosenbach4, Ruth Ann Vleugels5, John E. Harris1, Manuel Garber1 and Mehdi Rashighi1, 1UMass Chan Medical School, Worcester, MA, 2Spatial Genomics, Inc., Pasadena, CA, 3Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 4University of Pennsylvania, Philadelphia, PA, 5Brigham and Women's Hospital, Chestnut Hill, MA

    Background/Purpose: Inflammatory skin diseases vary widely in symptoms and causes. While ultraviolet (UV) light helps treat some like vitiligo and psoriasis, in conditions like cutaneous…
  • Abstract Number: 1967 • ACR Convergence 2025

    Developing an Algorithm to Quantify Dermatomyositis-Associated Calcinosis Using Infrared Imaging

    Saahil Sachdeva1, Briana Cervantes2, Lisa Rider3 and Adam Schiffenbauer4, 1NIEHS/NIBIB/NIH, Danville, CA, 2Department of Emergency Medicine, Norfolk, VA, 3National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, 4National Institute of Health/National Institute of Dental and Craniofacial Research, Bethesda, MD

    Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by chronic muscle and skin inflammation. One potential complication of DM is calcinosis, the heterotopic calcification…
  • Abstract Number: 1202 • ACR Convergence 2025

    High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort

    Ka Ki Yam1, Lucas Tsz Ho Luk1, Weng Nga Lao2, Chiu Wai Shirley Chan3, Dennis Tin Ho Chan4, Billy Tin Lok Lai5, Roy Tsz Chung Ho6, Vivian Hoi Shan Tang7, Ho So8 and Iris Tang9, 1Department of Medicine & Geriatrics, Hong Kong, Hong Kong, 2Department of Medicine & Geriatrics, Kwong Wah Hospital, Hong Kong, Hong Kong, 3Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, 4Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, 5Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, 6Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, 7Department of Medicine, North District Hospital, Hong Kong, Hong Kong, 8Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 9Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of idiopathic inflammatory myopathies (IIM), adversely impacting clinical outcomes. While the ACR/CHEST guideline recommends…
  • Abstract Number: 0286 • ACR Convergence 2025

    Anifrolumab For Treatment Of Refractory Juvenile Dermatomyositis In Adult Patients

    Connor Buechler1 and David Pearson2, 1University of Minnesota, Mendota Heights, MN, 2Department of Dermatology, University of Minnesota, Minneapolis, MN

    Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune connective tissue disorder with a chronic, relapsing course that can persist into adulthood. Current therapies exhibit widely variable…
  • Abstract Number: 2558 • ACR Convergence 2025

    Impact of Social Determinants of Health on Patient Perceptions of Home Infusion Therapy in the Treatment of Rheumatologic Conditions

    Leslie Myers1, Elizabeth Neal2, Edward O'Bryan1, Michele Way3 and Timothy Walton1, 1CSI Pharmacy, Nash, 2CSI Pharmacy, Nash, TX, 3CSI Pharmacy, Olathe, KS

    Background/Purpose: Home infusion therapy is an established alternative site of care for patients requiring administration of infusion medications through a needle or catheter. Supported by…
  • Abstract Number: 1956 • ACR Convergence 2025

    68Ga-FAPI-04 and 18F-FDG PET/ CT in MDA5 dermatomyositis-associated interstitial lung disease: a single-center, pilot study

    Jia Li1, Weijun Wei2, Lianghua Li2, Wenwen Xu3, Jianjun Liu2 and Shuang Ye4, 1Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), 2Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200217, China., Shanghai, China (People's Republic), 3Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200217, China., Shanghai, China (People's Republic), 4Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)

    Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in MDA5 dermatomyositis (MDA5-DM). Fibrosis and inflammation are pivotal drivers in the pathogenesis of…
  • Abstract Number: 1200 • ACR Convergence 2025

    Mortality in Idiopathic Inflammatory Myopathy in the Toulouse cohort (MIIRTALITY)

    Aurore Larrauffie1, Chloé Bost1, Marie Faruch1, Claire Barrier1, Jérémy Zordan1, Marie Guille1, Grégoire Prevot1, Thomas Villeneuve1, Morgane Mourguet1, Laurent Alric1, Laurent Sailler1, Martin Michaud1, Sébastien De Almeida Chaves1 and Grégory Pugnet2, 1CHU Toulouse, Toulouse, France, 2CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France

    Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are a group of heterogeneous connective tissue diseases including dermatomyositis (DM), polymyositis (PM), anti-synthetase syndromes (ASS), immune-mediated necrotizing myopathies (NM),…
  • 1
  • 2
  • 3
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology